EP3585420A4 - Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant - Google Patents

Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Download PDF

Info

Publication number: EP3585420A4
Authority: EP; European Patent Office
Prior art keywords: peptides; methods; same; related disorders; dystrophy
Prior art date: 2017-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP18756867.0A

Other languages

German (de)

English (en)

Other versions

EP3585420A2 (fr

Inventor

Eytan R. Barnea

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BioIncept LLC

Original Assignee

BioIncept LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-22

Filing date

2018-02-22

Publication date

2021-04-07

2018-02-22 Application filed by BioIncept LLC filed Critical BioIncept LLC

2018-02-22 Priority to EP22150813.8A priority Critical patent/EP4066850A3/fr

2020-01-01 Publication of EP3585420A2 publication Critical patent/EP3585420A2/fr

2021-04-07 Publication of EP3585420A4 publication Critical patent/EP3585420A4/fr

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP18756867.0A 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Withdrawn EP3585420A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP22150813.8A EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762462292P	2017-02-22	2017-02-22
PCT/US2018/019279 WO2018156801A2 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Division EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Publications (2)

Publication Number	Publication Date
EP3585420A2 EP3585420A2 (fr)	2020-01-01
EP3585420A4 true EP3585420A4 (fr)	2021-04-07

Family

ID=63253026

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant
EP18756867.0A Withdrawn EP3585420A4 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Country Status (6)

Country	Link
EP (2)	EP4066850A3 (fr)
CN (1)	CN110869044A (fr)
AU (1)	AU2018225163A1 (fr)
CA (1)	CA3054366A1 (fr)
IL (1)	IL268844A (fr)
WO (1)	WO2018156801A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160263186A1 (en) *	2013-10-22	2016-09-15	Bioincept, Llc	Pif-transfected cells and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8222211B2 (en)	2001-07-02	2012-07-17	Bioincept, Llc	Methods of administering PIF agonist peptides and uses thereof
CN100339388C (zh)	2001-07-02	2007-09-26	倍奥英赛普特有限责任公司	用于植入前因子的新型检测方法以及植入前因子肽
US7723290B2 (en)	2004-10-22	2010-05-25	Bioincept, Llc	Compositions and methods for modulating the immune system
US7723289B2 (en)	2003-10-22	2010-05-25	Bioincept, Llc	PIF tetrapeptides
CA2927595C (fr)	2004-12-22	2023-01-31	Ambrx, Inc.	Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
EP1793398A1 (fr)	2005-12-05	2007-06-06	Sokymat Automotive GmbH	Dispositif de fixation pour und composant électronique et unité de fabrication avec table tournante
CN101443358B (zh) *	2006-03-13	2016-05-11	利亚特·明茨	生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
US8916532B2 (en) *	2008-04-28	2014-12-23	The Trustees Of The University Of Pennsylvania	Methods for enhancing utrophin production via inhibition of microRNA
WO2010115050A2 (fr) *	2009-04-01	2010-10-07	The Regents Of The University Of California	Microarn spécifiques de cellules souches embryonnaires, qui favorisent la pluripotence induite
MX371526B (es)	2011-05-27	2020-01-31	Ambrx Inc	Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
JP6254527B2 (ja)	2011-10-07	2017-12-27	バイサイクル・セラピューティクス・リミテッド	構造化ポリペプチドの特異性のモジュレーション
CN104144695A (zh)	2012-02-15	2014-11-12	爱勒让治疗公司	***交联的和硫醚交联的拟肽大环化合物
ES2755104T3 (es)	2012-05-17	2020-04-21	Ra Pharmaceuticals Inc	Inhibidores peptídicos y peptidomiméticos
KR20150082307A (ko)	2012-11-01	2015-07-15	에일러론 테라퓨틱스 인코포레이티드	이치환 아미노산 및 이의 제조 및 사용 방법
WO2014138429A2 (fr)	2013-03-06	2014-09-12	Aileron Therapeutics, Inc.	Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
CN105979943A (zh) *	2013-10-25	2016-09-28	厄恩斯特.D.布什	肌营养不良的治疗方法
EP3193903A4 (fr) *	2014-09-16	2018-03-14	Bioincept LLC	Compositions et méthodes permettant le traitement d'un syndrome d'irradiation aiguë

2018
- 2018-02-22 EP EP22150813.8A patent/EP4066850A3/fr not_active Withdrawn
- 2018-02-22 CN CN201880026431.1A patent/CN110869044A/zh active Pending
- 2018-02-22 AU AU2018225163A patent/AU2018225163A1/en not_active Abandoned
- 2018-02-22 EP EP18756867.0A patent/EP3585420A4/fr not_active Withdrawn
- 2018-02-22 CA CA3054366A patent/CA3054366A1/fr active Pending
- 2018-02-22 WO PCT/US2018/019279 patent/WO2018156801A2/fr unknown
2019
- 2019-08-22 IL IL26884419A patent/IL268844A/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160263186A1 (en) *	2013-10-22	2016-09-15	Bioincept, Llc	Pif-transfected cells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIZIA PESSINA ET AL: "Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy", SKELETAL MUSCLE, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 25 August 2014 (2014-08-25), pages 7, XP021193544, ISSN: 2044-5040, DOI: 10.1186/2044-5040-4-7 *
UTPAL BASU ET AL: "Translational Regulation of Utrophin by miRNAs", PLOS ONE, vol. 6, no. 12, 27 December 2011 (2011-12-27), pages e29376, XP055751401, DOI: 10.1371/journal.pone.0029376 *

Also Published As

Publication number	Publication date
CN110869044A (zh)	2020-03-06
WO2018156801A2 (fr)	2018-08-30
CA3054366A1 (fr)	2018-08-30
EP4066850A3 (fr)	2022-11-23
WO2018156801A3 (fr)	2019-02-21
IL268844A (en)	2019-10-31
EP4066850A2 (fr)	2022-10-05
EP3585420A2 (fr)	2020-01-01
AU2018225163A1 (en)	2019-09-19

Legal Events

Date	Code	Title	Description
2018-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-12-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-12-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-01-01	17P	Request for examination filed	Effective date: 20190917
2020-01-01	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-01-01	AX	Request for extension of the european patent	Extension state: BA ME
2020-05-27	DAV	Request for validation of the european patent (deleted)
2020-05-27	DAX	Request for extension of the european patent (deleted)
2020-10-30	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40021181 Country of ref document: HK
2021-01-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/10 20060101ALI20201127BHEP Ipc: A61K 45/06 20060101ALI20201127BHEP Ipc: A61K 38/04 20060101ALI20201127BHEP Ipc: A61K 38/17 20060101ALI20201127BHEP Ipc: A61K 38/08 20190101ALI20201127BHEP Ipc: A61P 21/00 20060101ALI20201127BHEP Ipc: A61K 38/19 20060101AFI20201127BHEP
2021-04-07	A4	Supplementary search report drawn up and despatched	Effective date: 20210309
2021-04-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/19 20060101AFI20210302BHEP Ipc: A61K 38/10 20060101ALI20210302BHEP Ipc: A61K 45/06 20060101ALI20210302BHEP Ipc: A61K 38/17 20060101ALI20210302BHEP Ipc: A61K 38/08 20190101ALI20210302BHEP Ipc: A61K 38/04 20060101ALI20210302BHEP Ipc: A61P 21/00 20060101ALI20210302BHEP
2022-12-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2023-01-25	18D	Application deemed to be withdrawn	Effective date: 20220901

Publication	Publication Date	Title
EP3634430A4 (fr)	2021-04-14	Agents multibiotiques et procédés d'utilisation de ceux-ci
EP3496666A4 (fr)	2020-01-15	Dispositifs et procédés pour le traitement d'une insuffisance valvulaire
EP3474785A4 (fr)	2020-03-04	Implant vertébral et ses procédés d'utilisation
EP3720502A4 (fr)	2022-01-19	Produits cytobiologiques et leurs utilisations thérapeutiques
EP3442991A4 (fr)	2019-11-20	Peptides de liaison à ras et méthodes d'utilisation
EP3634442A4 (fr)	2021-05-26	Méthodes de traitement et de prévention de maladies
EP3478723A4 (fr)	2020-07-29	Anticorps spécifiques de pd-l1 et procédés pour les utiliser
EP3633034A4 (fr)	2021-03-24	PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3635418A4 (fr)	2021-03-03	Appareil et procédés d'évaluation de coupure de courant
EP3436476A4 (fr)	2020-04-29	Anticorps anti-ryk et leurs procédés d'utilisation
EP3684821A4 (fr)	2021-06-16	Anticorps anti-hla-a2 et leurs procédés d'utilisation
ZA201905851B (en)	2021-04-28	Peptides and methods for the treatment of diabetes
EP3651747A4 (fr)	2020-07-22	Compositions et méthodes de traitement de troubles oculaires
EP3558279A4 (fr)	2020-12-02	Compositions et méthode s pour le traitement d'une douleur chronique
EP3635000A4 (fr)	2021-04-14	Manabodies et procédés d'utilisation
EP3525703A4 (fr)	2020-04-22	Dispositifs et procédés de traitement
EP3678701A4 (fr)	2021-12-01	Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
EP3731867A4 (fr)	2022-04-06	Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3429584A4 (fr)	2019-11-13	Compositions et méthodes de traitement de la presbytie
EP3377085A4 (fr)	2019-07-17	Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
EP3348273B8 (fr)	2019-09-18	Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
EP3554626A4 (fr)	2020-06-03	Méthodes et dispositifs destinés au traitement de troubles d'origine vasculaire
EP3419425A4 (fr)	2020-01-08	Dispositifs de cuisson et leurs procédés d'utilisation
EP3615502A4 (fr)	2021-01-06	Composés et procédés thérapeutiques
EP3258930A4 (fr)	2018-10-17	Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress